Open AccessCombined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
Author(s) -
A.E.D. Van Swearingen,
M.J. Sambade,
M.B. Siegel,
S. Sud,
Riley McNeill,
S.M. Bevill,
Xuefeng Chen,
R.E. Bash,
L. Mounsey,
B.T. Golitz,
C. Santos,
A. Deal,
J.S. Parker,
N. Rashid,
C.R. Miller,
G.L. Johnson,
C.K. Anders
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/4qn4-n797
Subject(s) - triple negative breast cancer , breast cancer , cancer research , medicine , kinase , pi3k/akt/mtor pathway , triple negative , oncology , cancer , chemistry , biochemistry , signal transduction